Research progress on early stage extranodal natural killer/T cell lymphoma
10.3760/cma.j.cn113030-20201203-00583
- VernacularTitle:早期结外NK/T细胞淋巴瘤的研究进展
- Author:
Tian XU
1
;
Li YIN
;
Mengna ZHAN
;
Xinyu HU
;
Ke XUE
;
Shuai PEI
;
Xia HE
Author Information
1. 南京医科大学附属肿瘤医院 江苏省肿瘤医院 江苏省肿瘤防治研究所 210009
- Keywords:
Lymphoma/radiotherapy;
Lymphoma/chemotherapy;
Clinical staging;
Prognostic model
- From:
Chinese Journal of Radiation Oncology
2021;30(6):631-636
- CountryChina
- Language:Chinese
-
Abstract:
Extranodal natural killer/T-cell lymphoma (ENKTCL) is the subtype of non-Hodgkin lymphoma with high heterogeneity and invasiveness. Though most ENKTCL patients are present as early-stage at diagnosis, clinical prognosis significantly differs due to the limitations of clinical staging. Radiotherapy (RT) and chemotherapy (CT) are the first-line treatments for early ENKTCL patients. However, there is no consensus on the combined modalities of RT and CT, and their optimal strategy. With the continuous renewal of clinical staging and prognostic models, early-stage ENKTCL patients tend to accept risk-adapted treatment with proper stratification. In this review, the latest research progresses on clinical staging, prognostic models and treatment were retrospectively analyzed, aiming to provide references for clinical decision-making.
